Delandistrogene moxeparvovec (Elevidys) — Coverage Criteria for Duchenne muscular dystrophy
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
This medical benefit medication utilization policy defines coverage criteria, quantity limits, and authorization period for delandistrogene moxeparvovec (Elevidys) for members with Duchenne muscular dystrophy (DMD). It applies to providers seeking prior authorization for this therapy.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.